X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared IND for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy.
Lead Product(s): TSC-203-A0201
Therapeutic Area: Oncology Product Name: TSC-203-A0201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
TSC-200-A0201, a TCR-T targeting human papillomavirus 16 (HPV16) and the third TCR cleared for clinical development in the Company’s ImmunoBank following TSC-204-A0201 and TSC-204-C0702, which target MAGE-A1 presented on HLA types A*02:01 and C*07:02, respectively.
Lead Product(s): TSC-200-A0201
Therapeutic Area: Infections and Infectious Diseases Product Name: TSC-200-A0201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Under the terms of agreement, Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $530.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration May 09, 2023
Details:
TSC-101 targets MiHA, HA-1 and HA-2, respectively, to treat residual leukemia and prevent relapse following hematopoietic cell transplantation using reduced intensity conditioning for acute myeloid leukemia, myelodysplastic syndromes or acute lymphocytic leukemia.
Lead Product(s): TSC-101
Therapeutic Area: Oncology Product Name: TSC-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
TSC-204-A0201 targets melanomaassociated antigen 1 (MAGE-A1) on HLA types A*02 and C*07. MAGE-A1 is a cancer-associated antigen overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.
Lead Product(s): TSC-204-A0201
Therapeutic Area: Oncology Product Name: TSC-204-A0201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Lead Product(s): TSC-101
Therapeutic Area: Oncology Product Name: TSC-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The first four product candidates include a combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as novel targets for TCR-T therapy, such as TSC-201 and TSC-202.
Lead Product(s): TSC-203
Therapeutic Area: Oncology Product Name: TSC-203
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
TSC-100 and TSC-101, are designed to target HA-1 and HA-2, respectively, to prevent relapse in AML, ALL and MDS patients undergoing allogeneic haploidentical hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC).
Lead Product(s): TSC-101
Therapeutic Area: Oncology Product Name: TSC-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors which include combination of known targets, such as HPV16 for TSC-200 and PRAME for TSC-203, as well as novel targets for TCR-T therapy, such as TSC-201 and TSC-202.
Lead Product(s): TSC-203
Therapeutic Area: Oncology Product Name: TSC-203
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation.
Lead Product(s): TSC-101,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: TSC-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: K2 HealthVentures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
